Eli Lilly's phase III trial for orforglipron, an oral obesity treatment, shows promise as it may be easier and cheaper to produce than current options.
Retatrutide demonstrated unprecedented weight loss efficacy in its phase II trial, with participants losing 24.2% body weight over 11 months, surpassing previous drug effects.
Amgen's upcoming phase III trial for maritide aims to provide a monthly treatment that targets multiple pathways in blood sugar and metabolism for better obesity management.
Regulatory reviews for new treatments, including the non-opioid painkiller suzetrigine, highlight significant advancements in therapeutics for pain management and obesity.
Collection
[
|
...
]